Literature DB >> 15305153

Molecular identification, localization and function of platelet-type 12-lipoxygenase in human melanoma progression, under experimental and clinical conditions.

Erzsébet Rásó1, Balázs Döme, Beáta Somlai, Alex Zacharek, Wolfgang Hagmann, Kenneth V Honn, József Tímár.   

Abstract

As previous studies suggested the expression of a 12-LOX enzyme in murine and human melanoma cell lines, the primary aim of this project was to genetically identify the 12-LOX enzyme (platelet-, leukocyte- or epithelial form). By using reverse transcriptase-polymerase chain reaction, sequencing and various immunological techniques we have demonstrated conclusively the expression of the platelet-type 12-LOX in human melanoma cells of different origin, in their transplanted xenografts and in fresh human skin tumors. Furthermore, we found that p12-LOX is able to provide a survival signal for melanoma cells since inhibition of the enzyme by general LOX or selective 12-LOX inhibitors induced apoptosis in vitro. p12-LOX of human melanoma has been shown to be involved in the control of the metastatic phenotype, since we have detected the upregulation of the 12-LOX protein expression in spontaneously metastasizing xenografts and in thick human skin tumors (> 3.0 mm) characterized by high risk for the development of metastasis. Co-expression of two megakaryocytic genes, p12-LOX and alphaIIb integrin chains, was found to be a frequent phenomenon in human melanoma (approximately 70%) suggesting a common regulatory defect in this tumor. Copyright 2004 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15305153     DOI: 10.1097/01.cmr.0000138479.00897.d8

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  8 in total

Review 1.  12-lipoxygenase: a potential target for novel anti-platelet therapeutics.

Authors:  Jennifer Yeung; Michael Holinstat
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2011-07-01

2.  Arachidonate 12-lipoxygenase may serve as a potential marker and therapeutic target for prostate cancer stem cells.

Authors:  Bo Yin; Yang Yang; Zhiqiang Zhao; Yu Zeng; Steven M Mooney; Ming Li; Xuewen Xu; Yongsheng Song; Bin Wu; Zhibo Yang
Journal:  Int J Oncol       Date:  2011-01-11       Impact factor: 5.650

3.  Revisiting CB1 receptor as drug target in human melanoma.

Authors:  István Kenessey; Balázs Bánki; Agnes Márk; Norbert Varga; József Tóvári; Andrea Ladányi; Erzsébet Rásó; József Tímár
Journal:  Pathol Oncol Res       Date:  2012-03-24       Impact factor: 3.201

4.  Quantitative measurement of m-RNA levels to assess expression of cyclooxygenase-II, inducible nitric oxide synthase and 12-lipoxygenase genes in middle ear cholesteatoma.

Authors:  Tolgahan Çatlı; Yıldırım Bayazıt; Akın Yılmaz; Adnan Menevşe; Ozan Gökdoğan; Nebil Göksu; Suat Özbilen
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-07-06       Impact factor: 2.503

5.  Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection.

Authors:  Rosalina Wisastra; Petra A M Kok; Nikolaos Eleftheriadis; Matthew P Baumgartner; Carlos J Camacho; Hidde J Haisma; Frank J Dekker
Journal:  Bioorg Med Chem       Date:  2013-10-23       Impact factor: 3.641

Review 6.  Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology.

Authors:  Matthew W Buczynski; Darren S Dumlao; Edward A Dennis
Journal:  J Lipid Res       Date:  2009-02-24       Impact factor: 5.922

7.  Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?

Authors:  Marek Z Wojtukiewicz; Dominika Hempel; Ewa Sierko; Stephanie C Tucker; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

Review 8.  Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.

Authors:  Marek Z Wojtukiewicz; Dominika Hempel; Ewa Sierko; Stephanie C Tucker; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.